STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.
China NMPA approves Sciwind’s GLP-1 injection for diabetes
Sciwind Biosciences Co. Ltd. said Jan. 30 it won Chinese approval for self-developed glucagon-like peptide-1 (GLP-1) receptor agonist, ecnoglutide (Xianyida), to treat adults with type 2 diabetes.
Pfizer’s Metsera GLP-1 hits mark for once-monthly dosing
Nearly three months after winning a contentious bid to buy obesity drugmaker Metsera Inc. for $10 billion, Pfizer Inc. reported its first statistically significant top-line data of the acquired lead, ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, showing a mean placebo-adjusted weight loss of up to 12.3% at 28 weeks, as well as competitive tolerability.
GLP-1 drugs tied to lower-calorie, lower-sugar food purchases
Researchers at Steno Diabetes Center Copenhagen reported that starting a GLP-1 receptor agonist (GLP-1RA) coincided with slightly healthier supermarket purchases. Grocery purchases from GLP-1RA users in Denmark contained modestly fewer calories and sugars and slightly more protein per 100 g of food after treatment began than before.
Hormone Therapy Boosts Weight Loss on Tirzepatide for Postmenopausal Women
TUESDAY, Feb. 3, 2026 — Postmenopausal women who used hormone therapy lost significantly more weight while taking tirzepatide than women only taking tirzepatide, according to a study published online Jan. 22 in The Lancet Obstetrics, Gynaecology…
Novo’s Next-Gen Obesity Drug Beats Wegovy on Blood Sugar Control in Phase III
While CagriSema bested Novo Nordisk’s Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma’s 25% weight loss goal.
Updated: Do Pfizer’s monthly GLP-1 data justify Metsera’s $10B price tag?
Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on …
GLP-1 Pill Cut Heart Failure Events in Some Diabetes Patients
(MedPage Today) — Oral semaglutide (Rybelsus) protected against heart failure events in type 2 diabetes patients with a history of heart failure and either atherosclerotic cardiovascular disease, chronic kidney disease, or both, according to findings…
New CagriSema data show improvement over semaglutide
Novo Nordisk’s next-gen metabolic drug CagriSema performed better than the blockbuster semaglutide at reducing blood sugar and weight in patients with type 2 diabetes.
That was the topline result from the latest Phase 3 readout …
What is ‘food noise’? UK surgeon explains why people with obesity are more reactive to food; shares 5 ways to curb it
“Food noise” is a real thing where some brains experience heightened reward sensitivity associated with food. Dr Rajan explains how GLP-1 treatment can help.